This article is more than 5 years old. Information may no longer be current.

ThromboGenics receives FDA approval for new formulation of Jetrea

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The Office of Biotechnology Products of the FDA has approved an already diluted formulation of Jetrea, according to a press release from ThromboGenics.

The new Jetrea (ocriplasmin) formulation eliminates “the current preparatory dilution steps prior to injection.” According to the release, when Jetrea is administered to the eye, the strength, potency, composition and pharmaceutical form of the new formulation will remain identical to the currently available formulation of Jetrea after dilution.

ThromboGenics intends to launch the already diluted formulation of Jetrea in the first half of 2017.